Fig. 1: Response to CAR T-cell therapy. | Blood Cancer Journal

Fig. 1: Response to CAR T-cell therapy.

From: Impact of Extraosseous Extramedullary Disease on Outcomes of Patients with Relapsed-Refractory Multiple Myeloma receiving Standard-of-Care Chimeric Antigen Receptor T-Cell Therapy

Fig. 1

A Hematologic response rate for the EMD group. B Radiographic response rate for the EMD group. C Best overall tumor responses for the EMD (combined hematologic and radiographic response) and non-EMD groups. ORR overall response rate, CR complete response, VGPR very good partial response, PR partial response, heme hematologic, rads radiographic. * For response assessment at any time point, patients with missing data for rads or heme response, as well as deaths from toxicities/unrelated causes were considered as non-responders. Patients who died within the first 30 days post infusion prior to response assessment because of toxicities were also considered as non-responders.

Back to article page